Business Wire

EU Malaria Fund Enters Post-investment Period

7.10.2021 11:00:00 EEST | Business Wire | Press release

Share

On 30 September, the EU Malaria Fund (EUMF) concluded its investment activities at a high-level online event by finalizing its investments into four innovative companies active in malaria R&D. The EUMF has successfully expanded the pipeline of malaria R&D by funding nine promising and innovative malaria projects, covering treatments, vaccines, and diagnostics.

The COVID-19 pandemic has changed the game and led to the deployment of four EMA-approved, safe, and effective vaccines within less than 12 months. With this novel need to develop a large project on a now proven technology platform, the EUMF has successfully accomplished its mission earlier than expected. The EUMF will now enter its post-investment period.

The EUMF is grateful to the European Commission and the European Investment Bank (EIB), the major contributors to the Fund through the InnovFin EU programme funded by EU Horizon 2020 and the European Fund of Strategic Investments.

Other investors and supporters include the Investitionsbank Berlin, the Bill & Melinda Gates Foundation, Fondazione Monte Dei Paschi Di Siena, Jacques und Gloria Gossweiler Stiftung, Invethos AG, FINDdx, and Novartis AG. The fund was initiated by kENUP Foundation in cooperation with EIB and is managed by IBB Group Berlin.

The investments would not have been possible without the excellent work of the Funds Scientific Advisory Council and the Investment Decision Committee.

On 26 July, BioNTech SE announced the start of its Malaria project which aims at the development of a safe and highly effective malaria vaccine and the implementation of sustainable vaccine supply solutions on the African continent. The program was initiated by kENUP Foundation. Additional such programmes are currently being conceived and could cover other infectious diseases, such as tuberculosis and HIV.

Pedro Alonso, Director of the World Health Organization’s Global Malaria Programme, states: “The EU Malaria Fund is a great example how innovative new instruments can ultimately lead to impact. Malaria is the biggest killer of mankind. It affects the poorest and contributes to keeping them in poverty. I would like to thank everyone involved in the EU Malaria Fund project for their contribution to fighting malaria.”

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth: “Malaria is one of the most challenging diseases to beat and all efforts to find new vaccines or preventive means are important. For decades the European Union’s research and innovation programmes provided support to contribute to the global research agenda for malaria and we are committed to continue these efforts.“

Werner Hoyer, President of the European Investment Bank: “Malaria kills more than 1000 people each day – most of them children. Every step in the fight against the disease is welcome and much needed. Thanks to the successful work of the EU Malaria Fund, which financed nine promising projects, we significantly increased our chances to find new medications, diagnostics and vaccines. I am proud that the EIB is part of this effort.”

The video recording and more information can be found at https://www.controlmalaria.eu/news#conclusion

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tobias Mac-Lean, maclean@kenup.eu,+356 2169 5955

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release

Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help

AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release

FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m

Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release

Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t

Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release

Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release

Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye